CELC

Celcuity Inc.

Price Chart

Latest Quote

$87.76

-0.29 (-0.33%)

Current Price

Previous Close	$88.05
Open	$89.07
Day High	$89.40
Day Low	$82.55
Volume	1,825,005

Fetched: 2026-06-19T17:59:09

Stock Information

Shares Outstanding	48.77M
Total Debt	$323.44M
Cash Equivalents	$387.06M
Net Income	$-192.89M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$4.28B
EPS (TTM)	$-3.90
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$4.19B
Income	$-192.89M
Book/sh	$1.11
Cash/sh	$7.94
Employees	155

Financial Ratios

Quick Ratio	11.65
Current Ratio	12.31
Debt/Eq	604.28

Returns & Margins

ROA	-37.12%
ROE	-275.17%

Ownership

Insider Ownership	10.03%
Institutional Ownership	101.25%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	118.59
P/B	79.28

Analyst Data

Recommendation	none
Target Price	$161.09

Technical Indicators

SMA20	$104.73
SMA50	$118.04
SMA200	$97.38
RSI	16.04
ATR	8.4953

Shares Float	26.81M
Short Float	29.59%
Short Ratio	7.97
Volatility	0.12
Rel Volume	1.15

Performance History

Week	-1.93%
Month	-32.99%
Quarter	-22.33%
6 Months	-12.58%
YTD	-12.72%
Year	+644.99%
3 Years	+712.59%
5 Years	+226.25%
10 Years	+514.14%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$87.76	2,126,600
2026-06-17	$88.05	1,212,300
2026-06-16	$87.32	906,000
2026-06-15	$88.24	1,139,000
2026-06-12	$88.55	1,533,000
2026-06-11	$89.49	1,603,300
2026-06-10	$88.24	1,965,800
2026-06-09	$92.59	1,374,400
2026-06-08	$87.43	1,437,600
2026-06-05	$88.28	1,657,100
2026-06-04	$92.47	3,841,600
2026-06-03	$88.95	5,477,000
2026-06-02	$91.42	5,688,900
2026-06-01	$122.96	1,929,200
2026-05-29	$132.88	1,419,200
2026-05-28	$130.91	910,900
2026-05-27	$133.97	645,800
2026-05-26	$134.26	687,500
2026-05-22	$138.23	661,200
2026-05-21	$142.53	660,700
2026-05-20	$140.34	879,700
2026-05-19	$130.96	640,900

About Celcuity Inc.

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

📰 Latest News

Celcuity (CELC) Weighs Dilution Against Drug Development After $500 Million Convertible Note Offering

Simply Wall St. • 2026-06-04T19:11:20Z

Celcuity (CELC) Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patients

Insider Monkey • 2026-06-04T09:07:19Z

US Equity Futures Mixed Pre-Bell as US, Iran Continue Military Strikes in Middle East

MT Newswires • 2026-06-03T13:04:25Z

CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff?

Stocktwits • 2026-06-02T20:56:46Z

Celcuity Crashes On Breast Cancer Disappointment. What Happened?

Investor's Business Daily • 2026-06-02T20:28:49Z

Celcuity Says Gedatolisib Outperforms Novartis' Alpelisib Plus Fulvestrant in Phase 3 Trial

MT Newswires • 2026-06-02T19:09:51Z

Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial

BioPharma Dive • 2026-06-02T15:52:00Z

Celcuity Shares Fall Despite Strong Phase 3 Breast Cancer Trial Data (CELC)

InvestorsHub • 2026-06-02T13:40:13Z

Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More

Motley Fool • 2026-05-30T18:59:34Z

Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase

Motley Fool • 2026-05-17T20:46:06Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$17,148,000	$10,280,000	$5,326,387	$2,106,111
Total Expenses	$172,192,000	$113,267,000	$66,230,331	$39,391,091
Net Non Operating Interest Income Expense	$-4,850,000	$1,488,000	$2,451,215	$-978,949
Interest Expense Non Operating	$17,148,000	$10,280,000	$5,326,387	$2,106,111
Operating Expense	$172,192,000	$113,267,000	$66,230,331	$39,391,091
General And Administrative Expense	$27,197,000	$9,064,000	$5,636,326	$4,101,543
Other Income Expense	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-177,042,000	$-111,779,000	$-63,779,116	$-40,370,040
Net Interest Income	$-4,850,000	$1,488,000	$2,451,215	$-978,949
Interest Income	$12,298,000	$11,768,000	$7,777,602	$1,127,162
Normalized Income	$-177,042,000	$-111,779,000	$-63,779,116	$-40,370,040
Net Income From Continuing And Discontinued Operation	$-177,042,000	$-111,779,000	$-63,779,116	$-40,370,040
Total Operating Income As Reported	$-172,192,000	$-113,267,000	$-66,230,331	$-39,391,091
Net Income Common Stockholders	$-177,042,000	$-111,779,000	$-63,779,116	$-40,370,040
Net Income	$-177,042,000	$-111,779,000	$-63,779,116	$-40,370,040
Net Income Including Noncontrolling Interests	$-177,042,000	$-111,779,000	$-63,779,116	$-40,370,040
Net Income Continuous Operations	$-177,042,000	$-111,779,000	$-63,779,116	$-40,370,040
Pretax Income	$-177,042,000	$-111,779,000	$-63,779,116	$-40,370,040
Interest Income Non Operating	$12,298,000	$11,768,000	$7,777,602	$1,127,162
Operating Income	$-172,192,000	$-113,267,000	$-66,230,331	$-39,391,091
Special Income Charges	-	-	-	$0
Per Share
Diluted EPS	$-3.79	$-2.83	$-2.69	$-2.64
Basic EPS	$-3.79	$-2.83	$-2.69	$-2.64
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-159,727,000	$-101,369,000	$-58,309,957	$-38,053,011
Reconciled Depreciation	$167,000	$130,000	$142,772	$210,918
EBITDA (Bullshit earnings)	$-159,727,000	$-101,369,000	$-58,309,957	$-38,053,011
EBIT	$-159,894,000	$-101,499,000	$-58,452,729	$-38,263,929
Diluted Average Shares	$46,757,691	$39,449,393	$23,679,472	$15,418,543
Basic Average Shares	$46,757,691	$39,449,393	$23,679,472	$15,418,543
Diluted NI Availto Com Stockholders	$-177,042,000	$-111,779,000	$-63,779,116	$-40,370,040
Tax Provision	$0	$0	$0	$0
Research And Development	$144,995,000	$104,203,000	$60,594,005	$35,289,548
Selling General And Administration	$27,197,000	$9,064,000	$5,636,326	$4,101,543
Other Gand A	$27,197,000	$9,064,000	$5,636,326	$4,101,543
Total Unusual Items	-	-	-	$0
Total Unusual Items Excluding Goodwill	-	-	-	$0
Gain On Sale Of Ppe	-	-	-	$0

Fetched: 2026-06-16

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$100,555,000	$115,619,000	$139,769,322	$133,771,467
Total Assets	$466,558,000	$245,123,000	$191,219,398	$175,697,097
Total Non Current Assets	$899,000	$552,000	$628,801	$506,560
Other Non Current Assets	$349,000	-	-	-
Current Assets	$465,659,000	$244,571,000	$190,590,597	$175,190,537
Other Current Assets	$5,266,000	$2,698,000	$281,364	$351,073
Prepaid Assets	$18,896,000	$6,769,000	$8,920,603	$6,251,953
Cash Cash Equivalents And Short Term Investments	$441,497,000	$235,104,000	$180,582,748	$168,587,511
Cash And Cash Equivalents	$165,703,000	$22,515,000	$30,662,774	$24,571,557
Receivables	-	$1,600,621	$805,882	$0
Other Receivables	-	$1,600,621	$805,882	-
Current Deferred Assets	-	-	-	$33,195
Taxes Receivable	-	-	-	$203,665
Debt
Net Debt	$156,148,000	$75,212,000	$6,372,637	$10,411,517
Total Debt	$321,905,000	$97,953,000	$37,446,283	$35,238,274
Long Term Debt And Capital Lease Obligation	$321,851,000	$97,781,000	$37,261,333	$35,044,076
Long Term Debt	$321,851,000	$97,727,000	$37,035,411	$34,983,074
Current Debt And Capital Lease Obligation	$54,000	$172,000	$184,950	$194,198
Liabilities
Total Liabilities Net Minority Interest	$366,003,000	$129,504,000	$51,450,076	$41,925,630
Total Non Current Liabilities Net Minority Interest	$321,851,000	$97,781,000	$37,261,333	$35,044,076
Current Liabilities	$44,152,000	$31,723,000	$14,188,743	$6,881,554
Payables And Accrued Expenses	$35,760,000	$27,459,000	$12,182,983	$5,719,173
Interest Payable	$3,379,000	-	-	-
Payables	$6,407,000	$9,366,000	$5,076,699	$2,627,076
Accounts Payable	$6,407,000	$9,366,000	$5,076,699	$2,627,076
Equity
Common Stock Equity	$100,555,000	$115,619,000	$139,768,468	$133,770,346
Total Equity Gross Minority Interest	$100,555,000	$115,619,000	$139,769,322	$133,771,467
Stockholders Equity	$100,555,000	$115,619,000	$139,769,322	$133,771,467
Retained Earnings	$-448,897,000	$-271,855,000	$-160,076,003	$-96,296,887
Preferred Stock Equity	-	$318	$854	$1,121
Other
Ordinary Shares Number	$48,244,960	$37,143,242	$25,506,012	$21,667,250
Share Issued	$48,244,960	$37,143,242	$25,506,012	$21,667,250
Tangible Book Value	$100,555,000	$115,619,000	$139,768,468	$133,770,346
Invested Capital	$422,406,000	$213,346,000	$176,803,879	$168,753,420
Working Capital	$421,507,000	$212,848,000	$176,401,854	$168,308,983
Capital Lease Obligations	$54,000	$226,000	$410,872	$255,200
Total Capitalization	$422,406,000	$213,346,000	$176,804,733	$168,754,541
Additional Paid In Capital	$549,404,000	$387,437,000	$299,818,965	$230,045,566
Capital Stock	$48,000	$37,000	$26,360	$22,788
Common Stock	$48,000	$37,000	$25,506	$21,667
Preferred Stock	$0	$0	$854	$1,121
Long Term Capital Lease Obligation	$0	$54,000	$225,922	$61,002
Current Capital Lease Obligation	$54,000	$172,000	$184,950	$194,198
Pensionand Other Post Retirement Benefit Plans Current	$8,338,000	$4,092,000	$1,820,810	$968,183
Current Accrued Expenses	$29,353,000	$18,093,000	$7,106,284	$3,092,097
Net PPE	$550,000	$552,000	$628,801	$506,560
Accumulated Depreciation	$-2,159,000	$-1,992,000	$-1,861,990	$-1,719,218
Gross PPE	$2,709,000	$2,544,000	$2,490,791	$2,225,778
Leases	$304,000	$303,000	$302,577	$302,577
Other Properties	$51,000	$216,000	$400,019	$246,266
Machinery Furniture Equipment	$2,354,000	$2,025,000	$1,788,195	$1,676,935
Properties	$0	$0	$0	$0
Other Short Term Investments	$275,794,000	$212,589,000	$149,919,974	$144,015,954

Fetched: 2026-06-16

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-153,529,000	$-83,717,000	$-53,909,897	$-36,166,939
Operating Activities
Operating Cash Flow	$-153,280,000	$-83,467,000	$-53,812,253	$-36,008,171
Cash Flow From Continuing Operating Activities	$-153,280,000	$-83,467,000	$-53,812,253	$-36,008,171
Operating Gains Losses	-	-	-	-
Investing Activities
Capital Expenditure	$-249,000	$-250,000	$-97,644	$-158,768
Investing Cash Flow	$-64,084,000	$-63,069,000	$-5,008,207	$-144,031,794
Cash Flow From Continuing Investing Activities	$-64,084,000	$-63,069,000	$-5,008,207	$-144,031,794
Financing Activities
Issuance Of Capital Stock	$91,592,000	$63,608,000	$14,431,186	$100,497,832
Financing Cash Flow	$360,552,000	$138,388,000	$64,911,677	$120,325,141
Cash Flow From Continuing Financing Activities	$360,552,000	$138,388,000	$64,911,677	$120,325,141
Net Other Financing Charges	$-46,000	$-228,000	$-48,521	-
Net Common Stock Issuance	$91,592,000	$63,608,000	$14,431,186	$100,497,832
Common Stock Issuance	$91,592,000	$63,608,000	$14,431,186	$100,497,832
Other
Issuance Of Debt	$222,749,000	$59,226,000	$0	$19,509,037
Interest Paid Supplemental Data	$10,348,000	$7,586,000	$3,274,051	$1,255,280
End Cash Position	$165,703,000	$22,515,000	$30,662,774	$24,571,557
Beginning Cash Position	$22,515,000	$30,663,000	$24,571,557	$84,286,381
Changes In Cash	$143,188,000	$-8,148,000	$6,091,217	$-59,714,824
Proceeds From Stock Option Exercised	$46,257,000	$15,782,000	$50,531,461	$324,122
Net Issuance Payments Of Debt	$222,749,000	$59,226,000	$-2,449	$19,503,187
Net Long Term Debt Issuance	$222,749,000	$59,226,000	$-2,449	$19,503,187
Long Term Debt Issuance	$222,749,000	$59,226,000	$0	$19,509,037
Net Investment Purchase And Sale	$-63,835,000	$-62,819,000	$-4,910,563	$-143,873,026
Sale Of Investment	$332,507,000	$642,346,000	$309,614,521	$0
Purchase Of Investment	$-396,342,000	$-705,165,000	$-314,525,084	$-143,873,026
Net PPE Purchase And Sale	$-249,000	$-250,000	$-97,644	$-158,768
Purchase Of PPE	$-249,000	$-250,000	$-97,644	$-158,768
Change In Working Capital	$-2,652,000	$18,349,000	$3,859,410	$-1,191,914
Change In Other Current Assets	$-2,991,000	$2,770,000	$-3,438,018	$-5,526,381
Change In Payables And Accrued Expense	$12,466,000	$17,573,000	$7,297,428	$4,334,467
Change In Accrued Expense	$15,506,000	$13,257,000	$4,866,814	$3,257,387
Change In Payable	$-3,040,000	$4,316,000	$2,430,614	$1,077,080
Change In Account Payable	$-3,040,000	$4,316,000	$2,430,614	$1,077,080
Change In Prepaid Assets	$-12,127,000	$-1,994,000	-	$-5,621,480
Other Non Cash Items	$4,864,000	$2,845,000	$1,063,247	$704,660
Stock Based Compensation	$21,383,000	$6,988,000	$4,901,434	$4,638,205
Depreciation Amortization Depletion	$167,000	$130,000	$142,772	$210,918
Depreciation And Amortization	$167,000	$130,000	$142,772	$210,918
Depreciation	$167,000	$130,000	$142,772	$210,918
Net Income From Continuing Operations	$-177,042,000	$-111,779,000	$-63,779,116	$-40,370,040
Repayment Of Debt	-	$0	$-2,449	$-5,850
Long Term Debt Payments	-	$0	$-2,449	$-5,850
Sale Of PPE	-	-	-	$0
Change In Interest Payable	-	-	-	$-142,928
Change In Receivables	-	-	-	$95,099
Gain Loss On Sale Of PPE	-	-	-	$0
Change In Other Working Capital	-	-	-	-

Fetched: 2026-06-16